Atriphasic oral contraceptive pill, CTR-05: Clinical efficacy and safety

European Journal of Contraception and Reproductive Health Care

Volumn 1, Issue 3, 1996, Pages 285-292

  Singh, M ^a,b   Thomas, D ^a   Singh, R ^a   Saxena, B B ^a   Ledger, W J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Cholesterol; CTR 05; Desogestrel; High density lipoprotein; Low density lipoprotein; Oral contraceptives; Orthonovum

Indexed keywords

DESOGESTREL; ESTRADIOL DERIVATIVE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE DERIVATIVE; SEQUENTIAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HEADACHE; HUMAN; MENSTRUAL CYCLE; NAUSEA; RANDOMIZED CONTROLLED TRIAL;

ADULT; CHOLESTEROL, HDL; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SEQUENTIAL; DESOGESTREL; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FEMALE; HEADACHE; HUMANS; MENSTRUAL CYCLE; NAUSEA; NORETHINDRONE; PROGESTERONE CONGENERS;

EID: 0030223505     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.3109/13625189609150671     Document Type: Article

References (21)

1. Annual Birth Control Study, Ortho Pharmaceuticals Corporation, Rariton, New Jersey, 1991
2. Weijers MJ. Clinical trial of an oral contraceptive containing desogestrel and ethinyl estradiol. Clin Ther 1982; 4: 359-66
3. Rekers H. Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel. Acta Obstet Gynecol Scand 1988; 67: 171-4
4. Corson S. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand Suppl 1990; 152: 25-31
5. Walling MA. Multicenter efficacy and safety of an oral contraceptive containing 150 μg desogestrel and 30 μg ethinyl estradiol. Contraception 1992; 46: 313-26
6. Kaunitz AM. Combined oral contraception with desogestrel/ethinyl estradiol: tolerability profile. Am J Obstet Gynecol 1993; 168: 1028-33
7. Che RA. Clinical aspects of three new progestogens: desogestrel, gestodone, and norgestimate. Am J Obstet Gynecol 1989; 160: 1296-300
8. Shoupe D. Effects of desogestrel on carbohydrate metabolism. Am J Obstet Gynecol 1993; 168: 1041-7
9. Simon D, Senan C, Garnier P, et al. Effects of oral contraceptives on carbohydrate and lipid metabolism in a healthy population: the Telecom Study. Am J Obstet Gynecol 1990; 163: 382-7
10. Gaspard UJ, Lefebvre PJ. Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism and the development of cardiovascular disease. Am J Obstet Gynecol 1990; 163: 343
11. Krauss RM, Burkman RT. The metabolic impact of oral contraceptives. Am J Obstet Gynecol 1992; 167: 1177-84
12. Fotherby K. Oral contraceptives, lipids and cardiovascular disease. Contraception 1985; 31: 367-93
13. Cullberg G. Pharmacodynamic studies on desogestrel administered alone and in combination with ethinylestradiol. Acta Obstet Gynecol Scand 1985: Suppl 133: 1-30
14. Leuven JA, Dersjant-Roorda MC, Helmerhorst FM, et al. Estrogenic effect of gestodone or desogestrel-containing oral contraceptives on lipoprotein metabolism. Am J Obstet Gynecol 1990; 163: 358-62
15. Samsioe G, Mattsson L. Some aspects of the relationship between oral contraceptives, lipid abnormalities, and cardiovascular disease. Am J Obstet Gynecol 1990; 163: 354-8
16. Burkman R. Lipid metabolism effects with desogestrel-containing oral contraceptives. Am J Obstet Gynecol 1993; 168: 1033-40
17. Kloosterboer HJ, Rekers H. Effects of three combined oral contraceptive preparations containing desogestrel plus ethinyl estradiol on lipid metabolism in comparison with two levonorgestrel preparations. Am J Obstet Gynecol 1990; 163: 370-3
18. Gordon T, Kannel W, Castelli W, et al. Lipoproteins, cardiovascular disease and death. Arch Intern Med 1981; 141: 1128-31
19. Inman WHW, Vessey MP, Westerholm B, et al. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br Med J 1970; 2: 203-9
20. Lobo RA, Skinner JB, Lippman JS, et al. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertil Steril 1996; 65: 1100-9
21. Lammers P, op ten Berg M. Phase III clinical trial with a new oral contraceptive containing 150 μg desogestrel and 20 μg ethinyl estradiol. Acta Obstet Gynecol Scand 1991; 70; 497-500